Minyeong Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Minyeong Kim has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Seung-Hoon Baek
Department of Pharmacy and Research Institute of Pharmaceutical Science and Technology (RIPST), Ajou University, 16499 Suwon, Republic of Korea
3 shared publications - Ali Ali
Sheffield Teaching Hospitals NIHR Biomedical Research Centre, Sheffield S10 2JF, UK
1 shared publication - Arshad Majid
University of Sheffield
1 shared publication - David Burrows
Department of Neuroscience, SITraN, University of Sheffield, Sheffield S10 2HQ, UK
1 shared publication - Donghyun Kim
College of Pharmacy, Institute of Pharmaceutical Science and Technology, Hanyang University, Ansan 15588, Korea
1 shared publication - Eun-Sun Kim
College of Pharmacy, Institute of Pharmaceutical Science and Technology, Hanyang University, Ansan 15588, Korea
1 shared publication
Latest Publications
- 3 January 2022
- Published by Elsevier in Carbohydrate Polymers
- Vol. 281, 119057
Structure and antiviral activity of a pectic polysaccharide from the root of Sanguisorba officinalis against enterovirus 71 in vitro/vivo
- 3 January 2022
- Published by Elsevier in Carbohydrate Polymers
- Vol. 281, 119057
Structure and antiviral activity of a pectic polysaccharide from the root of Sanguisorba officinalis against enterovirus 71 in vitro/vivo
- Open Access
- 16 November 2021
- Published by MDPI AG in Applied Sciences
- Vol. 11 (22) , 10835
Characterization of an Immune-Enhancing Polysaccharide Fraction Isolated from Heat-Processed Ginseng Derived from Panax ginseng C.A. Meyer
Panax ginseng C.A. Meyer (ginseng) has shown immune-enhancing activity in many studies. The purpose of the present study was to analyze the chemical properties of a polysaccharide fraction (SGP) purified from heat- processed ginseng and to evaluate its immune-enhancing activity using RAW264.7 macrophages. The results showed that SGP increased inducible nitric oxide synthase expression and nitric oxide production in RAW264.7 macrophages. In addition, SGP increased mRNA expression and secretion of interleukin 6 and tumor necrosis factor alpha. Immunoblotting results showed that SGP increased the phosphorylation of mitogen-activated protein kinases (MAPKs) and NF-κB subunit p65 at 500 μg/mL and 1000 μg/mL. Taken together, SGP can activate macrophages through the MAPK and NF-κB signaling pathways, and it may help maintain homeostasis during viral and bacterial infections.
- 16 November 2021
- Published by MDPI AG in Applied Sciences
- Vol. 11 (22) , 10835
Open AccessCharacterization of an Immune-Enhancing Polysaccharide Fraction Isolated from Heat-Processed Ginseng Derived from Panax ginseng C.A. Meyer
Panax ginseng C.A. Meyer (ginseng) has shown immune-enhancing activity in many studies. The purpose of the present study was to analyze the chemical properties of a polysaccharide fraction (SGP) purified from heat- processed ginseng and to evaluate its immune-enhancing activity using RAW264.7 macrophages. The results showed that SGP increased inducible nitric oxide synthase expression and nitric oxide production in RAW264.7 macrophages. In addition, SGP increased mRNA expression and secretion of interleukin 6 and tumor necrosis factor alpha. Immunoblotting results showed that SGP increased the phosphorylation of mitogen-activated protein kinases (MAPKs) and NF-κB subunit p65 at 500 μg/mL and 1000 μg/mL. Taken together, SGP can activate macrophages through the MAPK and NF-κB signaling pathways, and it may help maintain homeostasis during viral and bacterial infections.
- Open Access
- 26 April 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (9) , 3053
Comparative Cerebroprotective Potential of d- and l-Carnosine Following Ischemic Stroke in Mice
L-carnosine is an attractive therapeutic agent for acute ischemic stroke based on its robust preclinical cerebroprotective properties and wide therapeutic time window. However, large doses are needed for efficacy because carnosine is rapidly degraded in serum by carnosinases. The need for large doses could be particularly problematic when translating to human studies, as humans have much higher levels of serum carnosinases. We hypothesized that d-carnosine, which is not a substrate for carnosinases, may have a better pharmacological profile and may be more efficacious at lower doses than l-carnosine. To test our hypothesis, we explored the comparative pharmacokinetics and neuroprotective properties of d- and L-carnosine in acute ischaemic stroke in mice. We initially investigated the pharmacokinetics of d- and L-carnosine in serum and brain after intravenous (IV) injection in mice. We then investigated the comparative efficacy of d- and l-carnosine in a mouse model of transient focal cerebral ischemia followed by in vitro testing against excitotoxicity and free radical generation using primary neuronal cultures. The pharmacokinetics of d- and l-carnosine were similar in serum and brain after IV injection in mice. Both d- and l-carnosine exhibited similar efficacy against mouse focal cerebral ischemia. In vitro studies in neurons showed protection against excitotoxicity and the accumulation of free radicals. d- and l-carnosine exhibit similar pharmacokinetics and have similar efficacy against experimental stroke in mice. Since humans have far higher levels of carnosinases, d-carnosine may have more favorable pharmacokinetics in future human studies.
- 26 April 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (9) , 3053
Open AccessComparative Cerebroprotective Potential of d- and l-Carnosine Following Ischemic Stroke in Mice
L-carnosine is an attractive therapeutic agent for acute ischemic stroke based on its robust preclinical cerebroprotective properties and wide therapeutic time window. However, large doses are needed for efficacy because carnosine is rapidly degraded in serum by carnosinases. The need for large doses could be particularly problematic when translating to human studies, as humans have much higher levels of serum carnosinases. We hypothesized that d-carnosine, which is not a substrate for carnosinases, may have a better pharmacological profile and may be more efficacious at lower doses than l-carnosine. To test our hypothesis, we explored the comparative pharmacokinetics and neuroprotective properties of d- and L-carnosine in acute ischaemic stroke in mice. We initially investigated the pharmacokinetics of d- and L-carnosine in serum and brain after intravenous (IV) injection in mice. We then investigated the comparative efficacy of d- and l-carnosine in a mouse model of transient focal cerebral ischemia followed by in vitro testing against excitotoxicity and free radical generation using primary neuronal cultures. The pharmacokinetics of d- and l-carnosine were similar in serum and brain after IV injection in mice. Both d- and l-carnosine exhibited similar efficacy against mouse focal cerebral ischemia. In vitro studies in neurons showed protection against excitotoxicity and the accumulation of free radicals. d- and l-carnosine exhibit similar pharmacokinetics and have similar efficacy against experimental stroke in mice. Since humans have far higher levels of carnosinases, d-carnosine may have more favorable pharmacokinetics in future human studies.